InSite Vision (ISV) Regains Development Rights for AzaSite Xtra
6/21/2013 9:53:44 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that the company has regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra™, from Inspire Pharmaceuticals Inc., a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada. AzaSite Xtra, formulated in InSite’s DuraSite® topical drug delivery system, is a product candidate intended for the topical treatment of ocular infections.
Help employers find you! Check out all the jobs and post your resume.
comments powered by